VHL vitasora health limited

http://www.euroinvestor.co.uk/news/story.aspx?id=1094983522-03-20...

  1. 520 Posts.
    http://www.euroinvestor.co.uk/news/story.aspx?id=10949835


    22-03-2010 - 08:30

    TRANSGENE : Transgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate StrategyTransgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy

    Parc d'Innovation, Illkirch, France, March 22, 2010 - Transgene (Euronext Paris: FR0005175080) details its major product milestones of 2009, provides a business update and outlines its corporate strategy.

    Key Product highlights:

    - TG4010 (MVA-MUC1-IL2), for the treatment of advanced non small cell lung cancer: confirmation of overall survival benefit of six months and FDA Fast Track status. In March 2010, Transgene granted Novartis an option for an exclusive worldwide license to the product.

    - TG4001/RG3484 (MVA-HPV-IL2), in partnership with Roche, for the treatment of precancerous cervical lesions caused by the HPV virus entered a large international phase IIb trial in October 2009 enrolling over 200 patients.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
2.6¢
Change
0.000(0.00%)
Mkt cap ! $44.68M
Open High Low Value Volume
2.6¢ 2.6¢ 2.6¢ $143.8K 5.533M

Buyers (Bids)

No. Vol. Price($)
1 68000 2.5¢
 

Sellers (Offers)

Price($) Vol. No.
2.7¢ 220386 3
View Market Depth
Last trade - 14.06pm 13/08/2025 (20 minute delay) ?
VHL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.